Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Form 8.3 - APH LN

14 Jan 2025 15:00

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Sand Grove Capital Management LLP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Fund(s) for which Sand Grove Capital Management LLP serves as the Investment Manager or Discretionary Sub-Advisor

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Alliance Pharma plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

13 January 2024

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

1p ordinary

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

12,312,879

2.28%

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

12,312,879

2.28%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

1p ordinary

Purchase

1,100,000

61.15p

1p ordinary

Purchase

3,800,000

61.1p

1p ordinary

Purchase

1,200,000

61.15p

1p ordinary

Purchase

1,800,000

61.1p

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:

14 January 2024

Contact name:

James Evans

Telephone number:

+44 203 161 0743

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114766379/en/

Copyright Business Wire 2025

Date   Source Headline
23rd Jan 201910:06 amRNSDirector Shareholding
21st Jan 20197:00 amRNSPre-Close Trading Update
2nd Jan 20194:00 pmRNSTotal Voting Rights
31st Dec 20187:00 amRNSBlock Listing Six Monthly Return
17th Dec 20187:00 amRNSAppointment of Non-Executive Directors
6th Dec 20187:00 amRNSTotal Voting Rights
12th Nov 20183:51 pmRNSDirector Share Dealing
7th Nov 20181:35 pmEQSHardman & Co Research: Alliance Pharma (APH): International brands driving performance
5th Oct 201810:25 amRNSGrant of Options to Directors
2nd Oct 20187:00 amRNSXonvea launch in the UK
19th Sep 20187:00 amRNSInterim results
16th Aug 20187:00 amRNSNotice of Results
10th Aug 201810:00 amRNSTotal Voting Rights
1st Aug 20189:56 amEQSHardman & Co Research: Alliance Pharma (APH): 2018: a year of international progress
25th Jul 20187:00 amRNSHalf Year Trading Update
6th Jul 20187:00 amRNSMarketing Authorisation for Diclectin
29th Jun 20187:00 amRNSBlock Listing Six Monthly Return
25th Jun 20189:39 amRNSNotification of Major Holdings
22nd Jun 201811:58 amRNSNotification of Major Holdings
21st Jun 20184:13 pmRNSCompletion of Acquisition and TVR
19th Jun 20182:24 pmRNSResult of Placing
19th Jun 20187:00 amRNSNizoral Acquisition in APAC and Proposed Placing
18th Jun 20185:19 pmRNSNotification of Major Holdings
18th Jun 20185:17 pmRNSNotification of Major Holdings
7th Jun 20187:00 amRNSPositive Opinion on Diclectin
5th Jun 20181:03 pmRNSTotal Voting Rights
30th May 20187:00 amRNSDirectorate Change
24th May 20184:05 pmRNSNotification of Major Holdings
24th May 201811:00 amRNSResult of AGM
24th May 20187:00 amRNSAGM Statement
16th May 20183:05 pmRNSNotification of Major Holdings
2nd May 201812:32 pmRNSTotal Voting Rights
19th Apr 20185:25 pmRNSAnnual Report and AGM Notice
19th Apr 20184:59 pmRNSNotification of Major Holdings
19th Apr 20187:17 amEQSHardman & Co Research: Alliance Pharma (APH): Entering the US market
17th Apr 20187:00 amRNSDisposal of Chinese rights to Forceval
13th Apr 20187:00 amRNSAlliance to present at the UK Investor Show
3rd Apr 20184:09 pmRNSTotal Voting Rights
27th Mar 20187:00 amRNSFull Year Results
6th Mar 20181:48 pmRNSTotal Voting Rights
1st Mar 20187:00 amRNSDirectorate Changes
8th Feb 20185:49 pmRNSTotal Voting Rights
8th Feb 20185:47 pmRNSNotification of Major Holdings
8th Feb 20187:00 amRNSNotification of Preliminary Results
29th Jan 201811:20 amRNSHardman Research: Strong Operational Cashflow
22nd Jan 20187:00 amRNSPre-Close Trading Update
11th Jan 20187:15 amRNSHardman Research: Acquisitions to boost growth
2nd Jan 20182:00 pmRNSTotal Voting Rights
2nd Jan 20187:00 amRNSBlock Listing Six Monthly Return
28th Dec 20177:00 amRNSCompletion of acquisition of Vamousse

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.